Cellyan Biotechnology Co., Ltd revenue

Cellyan Biotechnology Co., Ltd's revenue was $13.4m in fiscal 2026, down 33.9% on the year before. Since fiscal 2023 ($12.6m) it has grown at a compound 2.3% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cellyan Biotechnology Co., Ltd: revenue history, annual
Fiscal year	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Revenue	13	17	20	13
Growth on the year before	—	+32.9%	+21.7%	−33.9%
Gross profit	3	4	2	1
Gross margin	21.8%	21.3%	11.9%	10.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Distributors: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Cellyan Biotechnology Co., Ltd	$13.4m	-33.9%	—
Cosmos Health Inc.	$73.7m	33.8%	14.8%
111, Inc.	$1.75bn	-12.7%	—
Henry Schein	$13.60bn	6.5%	2.6%
Cencora	$332.77bn	5.1%	9.4%
McKesson	$410.98bn	8.8%	13.1%

Compare with peers

Head to head: COSM vs HKPD HKPD vs YI HKPD vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cellyan Biotechnology Co., Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cellyan Biotechnology Co., Ltd.